Cantani A, Micera M
Allergy and Clinical Immunology Division, Department of Pediatrics, University La Sapienza, Rome, Italy.
Eur Rev Med Pharmacol Sci. 2005 Mar-Apr;9(2):103-11.
Specific immunotherapy (SIT) in children being not an optional treatment should be administered as soon as possible, also in children aged 2-3 years, due to the very early asthma and rhinitis onset, contrarily to opponents continuing to stress the danger of anaphylactic reactions without displaying reliable data.
We report 56 children who underwent SIT and 56 controls seen consecutevely at the Allergy and Immunology Division, Department of Pediatrics, University of Rome "La Sapienza". The control group was treated with all appropriate medications.
They were highly in favor of SIT with statistically significant differences. We stress that IgE antibodies significantly decreased after treatment only in the study group, and IgG antibodies very significantly increased after treatment only in the study group.
We demonstrate that SIT is the only treatment which can alter the natural course of respiratory diseases, whereas drugs represent only a symptomatic treatment.
儿童特异性免疫疗法（SIT）并非一种可选择的治疗方法，由于哮喘和鼻炎发病极早，即便对于2至3岁的儿童也应尽早进行，这与反对者继续强调过敏反应的危险性却未提供可靠数据形成对比。
我们报告了56名接受SIT治疗的儿童以及56名在罗马第一大学儿科过敏与免疫科连续就诊的对照儿童。对照组接受了所有适当的药物治疗。
他们非常支持SIT，具有统计学上的显著差异。我们强调，仅在研究组中，治疗后IgE抗体显著降低，且仅在研究组中，治疗后IgG抗体非常显著地升高。
我们证明SIT是唯一能够改变呼吸道疾病自然病程的治疗方法，而药物仅为对症治疗。
Zotero 插件